Combining anticancer drugs with osteoprotective agents in prostate cancer—A contemporary update

I Tsaur, I Heidegger, A Kretschmer, H Borgmann, C Mirvald, G Gandaglia, A Briganti, R van den Bergh, D Tilki, P Ost, G Ploussard, G Surcel, C Surcel, on behalf of the EAU-YAU Prostate Cancer Working Party

Research output: Contribution to journalArticlepeer-review


Recently, a plethora of life-prolonging cytotoxic, next-generation hormonal, immunotherapeutical as well as radionuclide therapies has emerged as a standard care for metastasized castration-resistant prostate cancer. Being strikingly effective in cancer control, these novel therapies might in fact exert a beneficial impact on skeletal events. Therefore, combining anticancer drugs with osteoprotective agents might lead to additional clinical advantage but must be weighed against simultaneously exposing patients to serious toxicities. In addition, further survival prolongation by changing treatment paradigm in both metastasized hormone-sensitive and nonmetastatic castration-resistant disease might potentially increase the risk for bone density reduction complications due to a growing efficacy of androgen ablation leading to prolonged exposure. To address both possible indications of combined treatment and to draw practical conclusions, we performed a comprehensive review of the currently available evidence. © 2018 Elsevier Inc.
Original languageEnglish
Pages (from-to)488-497
Number of pages10
JournalUrologic Oncology: Seminars and Original Investigations
Issue number11
Publication statusPublished - 2018


Dive into the research topics of 'Combining anticancer drugs with osteoprotective agents in prostate cancer—A contemporary update'. Together they form a unique fingerprint.

Cite this